ArticleJAMA psychiatry2026
Cannabis Use Among Individuals With Psychosis After State-Level Commercial Cannabis Legalization.
Article in JAMA psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Emergency department use by individuals with and without psychosis after state-level cannabis legalization and commercialization.Nature. Mental health · 2026Article
- Who is at risk? Core mental health symptoms and problematic cannabis use in Germany.Journal of cannabis research · 2026Article
- How Consumers Transition Between Illicit and Legal Cannabis Markets in Early Legalization Periods? Evidence from a National Panel with a Recent Policy Shock.Research square · 2026Article
- Centering Individuals With Mental Illness as an At-Risk Group in the Era of Cannabis Legalization and Commercialization.Clinical therapeutics · 2026Article
- Psychotic Risk Associated With Cannabinoid Use: A Case Report of Ekbom-Like Delusional Infestation.Cureus · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Importance: Many individuals can use cannabis without harm, but individuals with psychosis are particularly vulnerable to negative effects from cannabis. No studies to date have investigated how recreational cannabis legalization (RCL) affects cannabis use in individuals with psychosis. Objective: To assess impacts of RCL in cannabis use among individuals who have ever been diagnosed with a psychotic illness or episode in the US. Design, Setting, and Participants: This study used data from 2014 to 2022 on state-level RCL with 5 years of follow-up from the Population Assessment of Tobacco and Health, a nationally representative longitudinal cohort study of 1856 adults aged 18 years and older in the US. The study sample consisted of individuals with a lifetime history of psychosis. Data were analyzed between January and June 2025. Main Outcomes and Measures: Percentage point (pp) changes in 30-day use of cannabis after RCL compared with control states using difference-in-differences methods. Results: The study sample consisted of 1856 individuals, with a mean age of 36.6 years (SD, 14.8 years) contributing 7465 responses, and was 50.2% White, 58.2% female, and had a 30-day cannabis-use rate of 31.8%. Individuals with psychosis in RCL states significantly increased their 30-day cannabis use by 9.53 pp (95% CI, 3.05-16.00 pp; P = .004), with sensitivity analyses showing significant estimates after retail outlets opened but not before, and no changes in higher frequency use. Conclusions and Relevance: In this study, individuals with psychosis reported a large increase in current cannabis use following legalization and commercialization of cannabis in their state, and by larger amounts than previously reported estimates of the general population. Given how cannabis can negatively affect illness course and health service utilization in individuals with psychosis, these results should be considered by regulators designing policies around taxation, potency, advertising, and health warnings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.